Background: Massive hemorrhage protocols (MHP) are critical to standardized delivery of timely, safe, and resource-effective coordinated care for patients with life-threatening bleeding.

Methods: A standardized MHP survey was sent to all hospitals (n = 150) in Ontario with a transfusion service. This study aim was to determine the proportion of hospitals with an MHP and assess for variability.

Results: The overall survey completion rate was 133 of 150 hospitals (89%) (remaining 17 providing negative affirmation that they did not have an MHP). An MHP was in place at 97 of 150 (65%) hospitals (60% of small (<5000 red cell units/year) vs. 91% of medium/large). A total of 10 different names of protocols were reported, with "Massive Transfusion Protocol" (68%) predominating. Activation criteria were present in 82 of 97 (85%); commonly activated based on volume of blood loss (70%). Blood work was drawn at the discretion of the physician (37%) or at predefined intervals (31%; majority every 60 min). Common routine laboratory tests performed were CBC (87%) and INR (84%). Fibrinogen testing was available at 88 (66%) of 133 reporting hospitals and part of the standard testing at 73 of 97 (75%) hospitals with an MHP. Median targets of hemostatic resuscitations, stated in the protocol at 49% of hospitals with an MHP, were: platelets >50 × 10/L, INR < 1.8, fibrinogen >1.5 g/L, and hemoglobin >70 g/L. Protocol required patient temperature monitoring in 65% and specified a reversal plan for patients on anticoagulants in 59%. At 36% of sites all patients are initially managed with O RhD negative blood. Overall, 61% of sites issue blood in predefined packs (vs. on demand). Hemostatic agents in protocols included: tranexamic acid (70%), prothombin complex concentrate (14%), fibrinogen concentrate (13%), and recombinant FVIIa (4%). Quality metrics were tracked in 32% of hospitals.

Conclusions: A third of hospitals lack formal MHPs, with the majority lacking in smaller hospitals. The survey results indicate that there is marked variability in all key aspects of the reported MHPs. This may be due to differences in hospital resources and personnel, lack of supporting evidence to dictate requirements, and differences in knowledge base of the individuals involved in protocol setting.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.injury.2018.11.026DOI Listing

Publication Analysis

Top Keywords

massive hemorrhage
8
marked variability
8
hospitals
7
mhp
5
hemorrhage protocol
4
survey
4
protocol survey
4
survey marked
4
variability absent
4
absent one-third
4

Similar Publications

Objective: This integrative review aims to evaluate the efficacy and safety of nebulized tranexamic acid (TXA) in managing hemoptysis, assessing its potential as a non-invasive alternative to traditional invasive procedures.

Methods: An integrative review was conducted in accordance with PRISMA guidelines and was registered on PROSPERO (CRD42024584812). The search included databases such as PubMed, EMBASE, Web of Science, and the Cochrane Central Register of Controlled Trials, encompassing studies published up to August 7, 2024.

View Article and Find Full Text PDF

Simultaneous Treatment of Pseudo-gynecomastia and Lateral Chest in Patients with Massive Weight Loss.

Aesthetic Plast Surg

January 2025

Department of Plastic, Burn and Maxillofacial Surgery, Ain Shams University, 7 Mohsen Roshdy street, Nasr City, Cairo, 11731, Egypt.

Background: Pseudogynecomastia in MWL patients is characterized by excess skin in chest, lateral chest, axilla and upper abdomen without enlargement of the breast glandular component. The aim of this work was to study long-term aesthetic outcomes of correction of severe pseudogynecomastia post-weight loss with inferior pedicle technique with some refinements.

Methodology: This prospective study included 15 patients underwent chest contouring after massive weight loss within period of 2 years between January 2022 and January 2024.

View Article and Find Full Text PDF

Biodegradable Polymeric Microspheres with Enhanced Hemostatic and Antibacterial Properties for Wound Healing.

Biomacromolecules

January 2025

National Engineering Research Center for Biomaterials, College of Biomedical Engineering, Sichuan University, Chengdu 610064, China.

Hemostasis is the initial step in wound healing, yet significant challenges, such as massive bleeding and infection, often arise. In this study, we developed amphiphilic biodegradable polyester-based segmented polyurethane (SPU) microspheres modified with epigallocatechin gallate (EGCG)-Ag nanoparticles and calcium-alginate cross-linking shell, combining blood absorption with the pro-coagulation properties of Ca and the negative charge of EGCG for synergistic hemostatic effects across various stages of the coagulation cascade. The in vitro blood clotting time of the SPU@EAg@CaAlg microsphere (328.

View Article and Find Full Text PDF

Dapagliflozin attenuates skeletal muscle atrophy in diabetic nephropathy mice through suppressing Gasdermin D-mediated pyroptosis.

Int Immunopharmacol

January 2025

School of Pharmacy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China; Hubei Engineering Research Center of Traditional Chinese Medicine of South Hubei Province, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China; Hubei Key Laboratory of Diabetes and Angiopathy, Xianning Medical College, Hubei University of Science and Technology, Xianning, Hubei, China. Electronic address:

Background: Skeletal muscle atrophy is a clinical concern in diabetic nephropathy, and without effective therapeutic approaches. Massive evidence has demonstrated that dapagliflozin, a sodium-glucose co-transporter 2 inhibitor can relieve diabetic nephropathy by inhibiting glucose re-absorption or podocyte pyroptosis. Nevertheless, whether dapagliflozin could treat skeletal muscle atrophy or the potential protection mechanism in diabetic nephropathy mice is unclear.

View Article and Find Full Text PDF

New surgical technique for managing placenta accreta spectrum and pilot study of the "CMNT PAS" study.

AJOG Glob Rep

February 2025

Tunis Medical Faculty, Tunis Centre for Maternity and Neonatal Care, Tunis El Manar University, Tunis, Tunisia (Abouda, Aloui, Azouz, Marzouk, Frikha, Hammami, Minjli, Hentati, Khila, Chanoufi, Karoui, and Hayen).

Introduction: The gold standard for treating the placenta accreta spectrum (PAS) is a cesarean hysterectomy, which harms fertility. Another conservative surgical approach allows the uterus to be preserved: one-step conservative surgery. We will compare these two approaches through the "CMNT PAS" study.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!